Wednesday, November 1, 2023
Loren Armenti
⭐Please note that this event is NOT closed to Wharton Alumni Angel members. Feel free to share this link with other angel groups who may be interested in learning more and joining this effort.
Members of Wharton Alumni Angels, Guindy Angels and Marvin's Angels are joining together for this opportunity to make a positive difference in the wake of current world events by making an investment in Cayuga Biotech, a Biopharma Company, through a convertible note with a 30% discount on conversion and an 8% interest rate.
Cayuga Biotech presented to Wharton Alumni Angel members at our 27-Sept Life Sciences Fast Track Pitch Event. Cayuga is developing a biomimetic drug designed to prevent death from hemorrhage under battlefield conditions. This can be lifesaving for our military in war-torn areas and the civilians caught up in the conflicts. Given current events the U.S. Department of Defense has seen the life-saving potential of Cayuga’s drug in its pipeline that stops bleeding and has agreed to allocate $3MM to quickly advance this treatment for human trials. The company is seeking incremental angel level funding to accelerate manufacturing and speed completion of the study.
Wharton Alumni Angels views this as a potential rare opportunity to play a role in saving lives at this critical time through an investment with updated attractive terms. WAA is leading the charge in aligning several additional Angel Investment Groups to raise the necessary capital to help in getting Cayuga over the finish line.
Wharton Alumni Angel member Jim Carroll ([email protected] or Jim Carroll on Slack) has agreed to spearhead this effort and is coordinating a due diligence call with Cayuga Biotech to provide a platform for Cayuga to update us on their latest developments.
Please join 1-cayuga-biotech on Slack to access updated information and to be kept up to date on this unique and time-sensitive development.